New data * showing the economic yoke of fragility fractures in the 27 member states of the European Union surpasses former estimates, with hip fractures accounting for about 55% of costs. The study was presented by the researchers at the European Congress of Osteoporosis & Osteoarthritis in Bordeaux.
The investigators used a population based model to estimate the economic burden of fractures in 2010, using data on facture incidence, costs for pharmaceutical prevention and post-fracture health care, mortality, and population size to estimate total costs. Data for hip, vertebral, wrist, "other fractures" were included and a societal perspective was used as far as possible. Costs were divided into cost of fractures occurring within the index year, cost of prior historic fractures that still are associated with costs, and cost of pharmaceutical prevention.
The total economic burden, including pharmaceutical prevention, of fractures in the European Union in 2010 was estimated at €39 billion EUR. The highest costs were in the EU's five largest countries - Germany (9.3 billion), Italy (7.2 billion), UK (5.6 billion), France (5 billion), Spain (2.9 billion).
John A. Kanis, Professor Emeritus at the University of Sheffield, WHO Collaborating Centre, and lead author of the study, concluded, "We have found that pharmaceutical prevention of fractures only accounts for 2 billion EUR in expenditure - approximately 5% of the total cost burden of fractures. This small investment in prevention and treatment reflects the fact that osteoporosis, which is most often the underlying cause of fragility fractures, is neither being assessed nor treated in the majority of people at high risk."
The economic burden of fractures in the European Union is expected to grow as as the number of seniors increases in Europe. Studies have estimated that the number of fractures will more than double by 2050 unless preventive action is taken.